Clinical Trials

Spago Nanomedical submitts clinical trial application

December 20, 2018

2284 Views

The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer.

The study is planned to be conducted in Sweden at Uppsala University Hospital. The intention is to start patient recruitment as soon as possible following regulatory approval.

The primary aim of the clinical trial is to document safety in patients with breast cancer. Another key aim is to investigate the contrast enhancement in MRI of primary and secondary tumors.

”The SpagoPix project is running according to plan and we have taken another step towards the target to offer a cancer selective and gadolinium free contrast agent for MRI of solid tumors”, says CEO Mats Hansen.

Malin Otmani

Transplant Drug Shows Promise

May 5, 2015

Veloxis Pharmaceuticals’ once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated that a lower, once-a-day dose of Envarsus XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to…

Evaxion announces promising Phase 1 data

June 1, 2023

Evaxion Biotech to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma at the 2023 ASCO annual meeting. “We are excited to report that the EVX-01 Phase 1 trial achieved its primary objectives. EVX-01 was well tolerated and induced a higher objective response rate than…

Ultimovacs completes enrollment in Phase II trial

August 10, 2023

Ultimovacs has announced the completion of enrollment of 75 patients and that the last patient has received the first dose in the FOCUS study. “We are pleased to announce the completion of patient enrollment in the FOCUS trial, the third of five randomized Phase II clinical trials evaluating UV1 in…

AlzeCure announces Phase IIa clinical study data

May 24, 2023

AlzeCure Pharma has received positive data from the clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain. The phase II data show that ACD440 was able to demonstrate positive proof-of-mechanism (PoM) results in patients with chronic peripheral neuropathic pain, i.e. the drug candidate has…